TW202342089A - 長效顆粒球巨噬細胞群落刺激因子 - Google Patents

長效顆粒球巨噬細胞群落刺激因子 Download PDF

Info

Publication number
TW202342089A
TW202342089A TW112113134A TW112113134A TW202342089A TW 202342089 A TW202342089 A TW 202342089A TW 112113134 A TW112113134 A TW 112113134A TW 112113134 A TW112113134 A TW 112113134A TW 202342089 A TW202342089 A TW 202342089A
Authority
TW
Taiwan
Prior art keywords
composition
cells
patient
csf
fusion
Prior art date
Application number
TW112113134A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 費德豪斯
繆小牛
王超
羅禕
鄒岳峰
Original Assignee
美商伴侶療法股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伴侶療法股份有限公司 filed Critical 美商伴侶療法股份有限公司
Publication of TW202342089A publication Critical patent/TW202342089A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW112113134A 2022-04-08 2023-04-07 長效顆粒球巨噬細胞群落刺激因子 TW202342089A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263329039P 2022-04-08 2022-04-08
US63/329,039 2022-04-08

Publications (1)

Publication Number Publication Date
TW202342089A true TW202342089A (zh) 2023-11-01

Family

ID=88243563

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112113134A TW202342089A (zh) 2022-04-08 2023-04-07 長效顆粒球巨噬細胞群落刺激因子

Country Status (9)

Country Link
US (1) US20250230210A1 (https=)
EP (1) EP4504262A4 (https=)
JP (1) JP2025511929A (https=)
KR (1) KR20250004698A (https=)
CN (1) CN119136831A (https=)
AU (1) AU2023248440A1 (https=)
CA (1) CA3247715A1 (https=)
TW (1) TW202342089A (https=)
WO (1) WO2023196747A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr
CN118909139A (zh) * 2024-07-24 2024-11-08 广东壹加再生医学研究院有限公司 一种活化树突状细胞的分子、方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
HUE070957T2 (hu) * 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
CA3070253A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
JP2023514972A (ja) * 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法

Also Published As

Publication number Publication date
EP4504262A1 (en) 2025-02-12
CA3247715A1 (en) 2023-10-12
AU2023248440A1 (en) 2024-10-17
KR20250004698A (ko) 2025-01-08
WO2023196747A1 (en) 2023-10-12
EP4504262A4 (en) 2026-04-15
US20250230210A1 (en) 2025-07-17
JP2025511929A (ja) 2025-04-16
CN119136831A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
JP2026048634A (ja) 獣医学用ｉｇｇ ｆｃ変異体
EP3896083B1 (en) Fc fusion proteins comprising novel linkers or arrangements
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
EP3463430B1 (en) Serum albumin-binding fibronectin type iii domains
KR20130056870A (ko) 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
RU2661087C2 (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину, и эффекторный компонент, и способы ее получения
TW202128961A (zh) 細胞激素融合蛋白及其醫藥組合物及治療應用
CN105593242A (zh) 卷曲螺旋免疫球蛋白融合蛋白及其组合物
US20220281939A1 (en) Modified tff2 polypeptides
TW202342089A (zh) 長效顆粒球巨噬細胞群落刺激因子
AU2016344134A1 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
KR20240028341A (ko) 융합 폴리펩티드
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
CN116507355A (zh) 粒细胞巨噬细胞集落刺激因子突变体
JP2023553117A (ja) 顆粒球マクロファージコロニー刺激因子の製造
CN118620057A (zh) Il-1r1胞外区多肽突变体及其用途
HK40066087A (zh) Cxcr4结合分子
HK40006036B (en) Serum albumin-binding fibronectin type iii domains
HK40006036A (en) Serum albumin-binding fibronectin type iii domains
KR20170027795A (ko) 항-사이토카인 항체의 동정을 위한 인간-유래 항-인간 il-20 항체 및 검정